PPMD is pleased to learn that Santhera Pharmaceuticals has launched a formal expanded access program in the U.S. for their investigational therapies, including idebenone. Learn more by visiting the Santhera website.
May 18, 2018 / Clinical Trials
by: Parent Project Muscular Dystrophy
PPMD is pleased to learn that Santhera Pharmaceuticals has launched a formal expanded access program in the U.S. for their investigational therapies, including idebenone. Learn more by visiting the Santhera website.
